• Immune Gene Modulation by Epigenetic Inhibitors in Melanoma

  2026-05-08

  Anichini et al. (2022) dissected how distinct epigenetic inhibitors reshape immune-related gene signatures in melanoma cells, revealing that DNMT inhibition by guadecitabine most robustly upregulates immune activation pathways. These findings clarify molecular mechanisms supporting epigenetic-immunotherapy combinations and highlight the need for precise inhibitor selection in translational oncology.

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-05-07

  Anlotinib hydrochloride delivers nanomolar, multi-pathway inhibition of angiogenesis, outperforming conventional TKIs in both in vitro and in vivo tumor models. This guide translates the latest mechanistic insights and experimental best practices for robust, reproducible endothelial migration and tube formation assays using APExBIO's validated compound.

• Dexamethasone (DHAP): Mechanistic Precision for Translationa

  2026-05-07

  Explore how Dexamethasone (DHAP), a synthetic glucocorticoid anti-inflammatory, enables next-generation translational research. This article integrates mechanistic insights—NF-κB inhibition, stem cell differentiation, autophagy induction—with workflow strategy, competitive benchmarking, and clinical context. Evidence-based guidance empowers researchers to drive discovery from bench to bedside.

• SDHB Palmitoylation Drives T Cell Exhaustion in Pancreatic C

  2026-05-06

  This study uncovers how DHHC5-mediated palmitoylation of succinate dehydrogenase B (SDHB) in pancreatic cancer cells stabilizes SDHB, enhancing fumarate production and promoting T cell exhaustion via the H3K27ac-PD1 axis. The findings provide mechanistic insight into tumor immune evasion and propose a peptide inhibitor targeting SDHB palmitoylation as a promising adjunct to immunotherapy.

• Amikacin Sulfate (SKU C8696): Reliable Solutions for Cell As

  2026-05-06

  This scenario-driven guide examines how Amikacin Sulfate (SKU C8696) offers reproducible, data-backed solutions to laboratory challenges encountered in cell viability and bactericidal assays. Drawing on validated protocols and quantitative evidence, the article provides actionable insights for researchers working with non-tuberculous mycobacterial and staphylococcal models.

• Morin Inhibits AMPD to Restore Podocyte Energy in Fructose I

  2026-05-05

  This study reveals how Morin, a natural flavonoid, counteracts high-fructose-induced podocyte mitochondrial dysfunction by targeting adenosine 5′-monophosphate deaminase (AMPD), particularly the AMPD2 isoform. These mechanistic insights highlight Morin’s therapeutic potential for glomerular injury linked to metabolic stress.

• 3X (DYKDDDDK) Peptide: Structural Precision for Protein Scie

  2026-05-05

  Explore the 3X (DYKDDDDK) Peptide as an advanced epitope tag, emphasizing its structural and biophysical advantages for recombinant protein studies. This article offers new insights into metal interactions, crystallography, and assay design strategies.

• Lypressin Acetate: Translational Insights from Receptor Agon

  2026-05-04

  Explore how Lypressin acetate, a lysine vasopressin analog, bridges antidiuretic hormone research and emerging antiviral strategies. This article delivers an in-depth perspective on pharmacological mechanisms, quantitative assay guidance, and translational challenges, setting it apart from prior coverage.

• AG-490: Advancing JAK2/STAT6 Modulation in Tumor Immunity

  2026-05-04

  This thought-leadership article explores the mechanistic, experimental, and translational significance of AG-490 (Tyrphostin B42) as a precision tool for dissecting JAK2/STAT6-driven macrophage polarization in cancer. Bridging foundational research—including the latest findings on exosomal SNORD52 in hepatocellular carcinoma (HCC)—with strategic guidance for translational teams, we position AG-490 not just as a kinase inhibitor, but as a catalyst for next-generation tumor-immune microenvironment studies. The article integrates evidence, protocol parameters, and competitive context, and provides a visionary outlook for researchers seeking to model and manipulate immunopathological states for translational impact.

• I-BET151 (GSK1210151A): BET Bromodomain Inhibitor Workflows

  2026-05-03

  I-BET151 (GSK1210151A) is a selective BET bromodomain inhibitor designed to modulate transcriptional programs in cancer biology, notably supporting apoptosis and cell cycle arrest assays. This compound is intended for preclinical research workflows involving BET protein modulation and is not suitable for diagnostic or clinical applications.

• MHY1485 (SKU B5853): A Reliable mTOR Activator for Reproduci

  2026-05-02

  This article delivers a scenario-driven, evidence-based guide to optimizing cell viability, proliferation, and autophagy assays using MHY1485 (SKU B5853). Drawing on peer-reviewed data and explicit workflow recommendations, it addresses real-world experimental challenges and positions MHY1485 from APExBIO as a reliable, high-utility tool for mTOR signaling research.

• MAPK10-Mediated KRT16 Degradation Suppresses NSCLC Metastasi

  2026-05-02

  The referenced study uncovers how MAPK10 suppresses non-small cell lung cancer (NSCLC) metastasis by phosphorylating keratin 16 (KRT16), leading to its ubiquitination and proteasomal degradation. These findings reveal a mechanistic axis that may serve as both a prognostic biomarker and a therapeutic target, with practical implications for designing experiments probing phosphorylation-dependent cancer signaling.

• Entecavir (BMS200475): Molecular Precision in Chronic HBV Th

  2026-05-01

  Explore the advanced molecular pharmacology of Entecavir, a potent inhibitor of chronic hepatitis B virus replication. This article reveals how recent research and clinical data translate into optimized experimental and therapeutic strategies.

• Practical Guide to Calpain Inhibitor I, ALLN: Protocols & QC

  2026-04-30

  Calpain Inhibitor I, ALLN is a selective, potent inhibitor of calpain and cathepsin proteases, supporting workflows in apoptosis assays and ischemia-reperfusion injury models. It is best suited for research applications requiring precise modulation of cysteine protease activity, but should not be used in diagnostic or clinical settings. This guide outlines optimal handling, protocol parameters, and typical troubleshooting steps for researchers using this reagent.

• PreScission Protease: HRV 3C Precision in Protein Purificati

  2026-04-30

  PreScission Protease (PSP) from APExBIO delivers ultra-specific HRV 3C protease cleavage, enabling efficient, low-temperature removal of fusion tags for sensitive protein studies. Its optimized workflow supports robust recovery of native proteins, even within challenging chromatin and condensate applications.

423 records 17/29 page Previous Next First page 上5页 1617181920 下5页 Last page